HC Wainwright & Co. Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) but lowered the price target from $20 to $14.
June 11, 2024 | 10:16 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Reviva Pharmaceuticals but lowered the price target from $20 to $14. This indicates continued confidence in the company's prospects, albeit with a more conservative valuation.
The maintained Buy rating suggests that the analyst still sees potential in Reviva Pharmaceuticals, but the lowered price target reflects a more cautious outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100